Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial
This analysis of SUNLIGHT showed that patients treated with FTD/TPI + bevacizumab had no clinically relevant changes in QoL, and prolonged TTDD and time to ECOG PS worsening, compared to patients treated with FTD/TPI.
Authors
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- L. Roby
- Julien Taı̈eb (ORCID: https://orcid.org/0000-0002-9955-4753)
- Gerald W. Prager (ORCID: https://orcid.org/0000-0002-7854-7781)
- Fortunato Ciardiello (ORCID: https://orcid.org/0000-0002-4661-5540)
- Elizabeth Calleja
- Marwan Fakih (ORCID: https://orcid.org/0000-0002-6554-5488)
- Nadia Amellal (ORCID: https://orcid.org/0000-0002-6171-6729)
- Valentine Barboux
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
- Gemma Soler
Institutions
- Délégation Paris 5 (FR)
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Université Paris Cité (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Institut Català d'Oncologia (ES)
- City of Hope (US)
- Taiho Oncology (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli (IT)
- Servier (France) (FR)
- Medical University of Vienna (AT)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical Colorectal Cancer
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1016/j.clcc.2024.12.002
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Servier
- Institut de Recherches Servier